Consistent with the findings from the TCGA-LIHC dataset, higher PRMT3 expression was also strongly associated with shorter overall survival and progression-free survival of HCC patients in the SYSUCC cohort (Fig. 1D). Here, PRMT3 is linked to hepatocellular carcinoma.